H.C. Wainwright has initiated coverage on Mural Oncology (NASDAQ: MURA), assigning the stock a Buy rating with an $18.00 price target.
The firm's optimism is rooted in the potential of Mural Oncology's nemvaleukin alfa, an engineered interleukin-2 (IL-2) cytokine designed to enhance the therapeutic effects of high-dose recombinant human IL-2 while reducing its harmful side effects.
Mural Oncology is expected to release interim overall survival data from the Phase 3 ARTISTRY-7 study, which combines nemvaleukin with pembrolizumab in patients with platinum-resistant ovarian cancer, between late March 2025 and early June 2025. This will be followed by top-line results from cohort 2 of the Phase 2 ARTISTRY-6 study in mucosal melanoma.
Despite the historical skepticism towards cytokine modalities due to past failures, H.C. Wainwright believes that nemvaleukin's innovative engineering sets it apart as a leader in its class. The firm anticipates multiple approvals in oncology for this class of treatments over the next five years. The analyst pointed out that the market has unfairly grouped all next-generation cytokine stocks together, presenting an attractive investment opportunity in Mural Oncology.
The firm's thesis is based on the high probability of nemvaleukin expanding to additional tumor types, supported by previous efficacy shown by Proleukin. H.C. Wainwright's base case assumes that nemvaleukin will first be approved for use in platinum-resistant ovarian cancer in the second half of 2026, followed by mucosal melanoma in 2029, with the possibility of application in cutaneous melanoma by 2030.
In other recent news, Mural Oncology has seen significant changes in its board of directors. The pharmaceutical company recently announced the appointment of Sachiyo Minegishi and George Golumbeski to its board. Minegishi, recognized as an independent director under Nasdaq rules, assumed her role as Chair of the Audit Committee and a member of the Nominating and Corporate Governance Committee. Golumbeski, a veteran in business development, also joined the board as an independent director.
Both appointments are set to expire at the company's 2025 annual general meeting. As part of their compensation, both Minegishi and Golumbeski received an option to purchase over 15,000 ordinary shares at $3.38 per share, vesting over three years contingent upon continued service.
InvestingPro Insights
Recent data from InvestingPro sheds additional light on Mural Oncology's financial position and market performance. The company's market capitalization stands at $63.38 million, reflecting its current valuation in the biotech sector. Notably, Mural Oncology has seen a significant return of 8.77% over the last week, aligning with the positive sentiment expressed in H.C. Wainwright's initiation report.
InvestingPro Tips highlight that Mural Oncology holds more cash than debt on its balance sheet, which could be crucial for funding ongoing clinical trials and potential commercialization efforts for nemvaleukin alfa. This financial stability is particularly important given the company's current unprofitable status and the projected timeline for potential drug approvals.
However, investors should note that the company is quickly burning through cash, which is not uncommon for biotech firms in the development stage. This factor underscores the importance of the upcoming clinical trial results in potentially attracting further investment or partnerships.
For those interested in a deeper analysis, InvestingPro offers 10 additional tips for Mural Oncology, providing a more comprehensive view of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.